Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

13.110
-1.050-7.42%
Volume:3.64M
Turnover:47.84M
Market Cap:13.91B
PE:-43.63
High:14.000
Open:14.000
Low:12.680
Close:14.160
52wk High:18.750
52wk Low:4.090
Shares:1.06B
HK Float Shares:1.06B
Volume Ratio:2.66
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.300
ROE:-12.77%
ROA:-12.32%
PB:6.55
PE(LYR):-43.63
PS:5172.16

Loading ...

BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026

Reuters
·
Mar 17

Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets

Reuters
·
Mar 17

ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models

Stock News
·
Mar 17

Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026

THOMSON REUTERS
·
Mar 17

Ascletis says ASC39 delivered 6.6% placebo-adjusted weight loss in obese rats and targets US FDA IND filing in Q3 2026

Reuters
·
Mar 17

HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.

Tiger Newspress
·
Mar 17

BRIEF-Ascletis Announces Positive Topline Results from U.S. Phase II for Its Ultra-Long-Acting GLP-1R Agonist ASC30 for Obesity

Reuters
·
Mar 10

Ascletis Pharma Inc - Asc30 Achieves 7.5% Placebo-Adj Mean Weight Loss at Week 16 After Three Monthly Doses

THOMSON REUTERS
·
Mar 10

Ascletis Pharma Inc - No Discontinuations Due to Adverse Events for Asc30 or Placebo

THOMSON REUTERS
·
Mar 10

Ascletis Pharma Inc - Asc30 Demonstrates Safety Profile Consistent With Glp-1 Drug Class

THOMSON REUTERS
·
Mar 10

Ascletis Pharma Inc: Asc30 Phase Ii Study Achieved Its Primary Endpoint

THOMSON REUTERS
·
Mar 10

Ascletis Pharma Inc - Asc30 Maintains Weight Loss for Four Months After Final Monthly Dose

THOMSON REUTERS
·
Mar 10

Ascletis Announces Positive Topline Results From U.S. Phase Ii, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule Glp-1R Agonist Asc30 for Obesity

THOMSON REUTERS
·
Mar 10

ASCLETIS-B's Long-Acting GLP-1 Candidate Shows Promising Weight Loss in U.S. Phase II Trial

Stock News
·
Mar 10

Ascletis reports Phase II ASC30 depot achieves 8% placebo-adjusted weight loss at week 16

Reuters
·
Mar 10

Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities

Bulletin Express
·
Mar 03

Hong Kong Market Enters Era of Pricing Power Stratification as Mainland's 1.41 Trillion HKD Southbound Flows Anchor Market While Korean Retail Investors Ignite Speculative Activity

Stock News
·
Feb 13

Assessing Ascletis Pharma (SEHK:1672) Valuation After New Obesity And Acne Pipeline Updates

Simply Wall St.
·
Feb 11

Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies

MT Newswires Live
·
Feb 11

BRIEF-Ascletis Pharma Selects Asc36 For Clinical Development

Reuters
·
Feb 11